Facial Injectables Market Outlook:
Facial Injectables Market size was over USD 11.64 billion in 2025 and is anticipated to cross USD 29.38 billion by 2035, witnessing more than 9.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of facial injectables is assessed at USD 12.66 billion.
The growth of the facial injectables market is set to be dominated by growing concerns among the geriatric population related to face wrinkles, fine lines, and volume loss. For instance, as per the predictions of the World Health Organization, 1 in 6 people across the globe by 2030, is predicted to be aged 60 years or over. Therefore, facial injectables are ideal for the aged population who want fresh skin.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of facial injectables is assessed at USD 12.66 billion.
The global facial injectables market size surpassed USD 11.64 billion in 2025 and is projected to witness a CAGR of over 9.7%, crossing USD 29.38 billion revenue by 2035.
The North America facial injectables market is predicted to capture 32% share by 2035, fueled by rising spending on cosmetics and appearance.
Key players in the market include Allergan (AbbVie), Galderma S.A., Merz Pharma GmbH & Co. KGaA, Sinclair Pharma, Teoxane Laboratories, Suneva Medical, Inc., Anika Therapeutics, Inc., BioPlus Co., Ltd., Medytox Inc., Croma-Pharma GmbH.
